12:00 AM
 | 
Jun 09, 2014
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Alexion sales and marketing update

Alexion recalled nine additional lots of Orphan drug Soliris eculizumab distributed in the U.S. due to the presence of visible particles. Alexion said there has not been any identifiable safety concern attributed to the lots. The company believes that it has identified the filling...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >